Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zellwerk GmbH has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner and is located in 1 distinct art unit. The concentration of the company's current prosecution into 1 pending office action indicates a narrow approach to its patent filings in the biotechnology sector. This structure limits the complexity of managing simultaneous office actions.
The busiest examiner for the portfolio is MIANO, JOSEPH PAUL, who is responsible for 1 busiest examiner pending action. Given that the total number of pending office actions is 1, MIANO, JOSEPH PAUL is the only examiner currently interacting with the company. The reliance on 1 distinct art unit means that the company's patent prospects are subject to the specific standards of that 1 group. Practitioners must focus on the particular requirements of this 1 distinct examiner to advance the 1 pending office action toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041487 | METHOD FOR PRODUCING TUMOR-INFILTRATING T-LYMPHOCYTES (TIL) AND THEIR USE AS CELLULAR THERAPEUTICS FOR THE TREATMENT OF HUMAN TUMORS | MIANO, JOSEPH PAUL | 44d overdue |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18041487 | METHOD FOR PRODUCING TUMOR-INFILTRATING T-LYMPHOCYTES (TIL) AND THEIR USE AS CELLULAR THERAPEUTICS FOR THE TREATMENT OF HUMAN TUMORS | MIANO, JOSEPH PAUL | 1631 | §103 | Final Rejection | 44d overdue | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial